574
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Genomic profile of breast cancer

, , &

References

  • Seguí MA , Crespo C , Cortés J , et al. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective. Expert Rev Pharmacoecon Outcomes Res 2014;14(6):889-99
  • Denduluri N , Rugo HS , Davis SE , et al. Concordance between the 21-gene recurrence score (RS) and the 70-gene profile (MP) in breast cancer (BC) patients (pts). J Clin Oncol 2011;29(Suppl 27; Abstract 13
  • Poulet B , Jamshidian F , Butler S , et al. Risk classification of early stage breast cancer as assessed by MammaPrint and Oncotype DX genomic assays. 2012 San Antonio Breast Cancer Symposium. Abstract #P6-07-03
  • Shivers SC , Clark L , Esposito N , et al. Direct comparison of risk classification between MammaPrint®, Oncotype DX® and MammoStrat® assays in patients with early stage breast cancer. 2013 San Antonio Breast Cancer Symposium; Abstract #P6-07-03
  • Paik S , Tang G , Shak S , et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34
  • Albain KS , Barlow WE , Shak S , et al. Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in a Randomized Trial of Chemotherapy for Postmenopausal, Node-Positive, Estrogen Receptor-Positive Breast Cancer. Lancet Oncol 2010;11(1):55-65
  • Knauer M , Mook S , Rutgers EJ , et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010;120(3):655-61
  • Estevez LG , Calvo I , Abad MF , et al. A retrospective study in the Spanish population with Oncotype DX recurrence score (RS) in breast cancer patients with positive and negative-lymph nodes. 2013 ASCO Annual Meeting; Abstract No. e11531
  • Caro JJ , Briggs AH , Siebert U , Kuntz KM . ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices-overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health 2012;15(6):796-803

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.